Publications by authors named "S Calbo"
Article Synopsis
- Pemphigus vulgaris (PV) is an autoimmune disease marked by autoantibodies targeting adhesion proteins and is associated with the HLA-DRB1*0402 gene, with treatment involving rituximab and corticosteroids leading to disease control.
- The study aimed to assess how rituximab affects specific T lymphocyte subpopulations that regulate B-cell responses, particularly follicular helper T (Tfh) and follicular regulatory T (Tfr) cells, in patients with PV.
- Findings revealed a decrease in autoreactive Dsg3-specific Tfh cells post-rituximab treatment, alongside the emergence of a notable Tfr subpopulation, indicating that these Tfr cells may play a role
Article Synopsis
- The Ritux 3 trial showed that rituximab is effective and safe as a first-line treatment for pemphigus, although long-term follow-up data was previously lacking.!* -
- This 7-year follow-up study evaluated the long-term outcomes for patients treated with rituximab alongside prednisone versus those treated with prednisone alone, focusing on disease-free survival and relapse rates.!* -
- Results indicated that 93% of patients in the rituximab group achieved complete remission without corticosteroids, showing significantly higher disease-free survival and lower relapse rates compared to the prednisone-only group.!*
Severe acute respiratory syndrome-Coronavirus 2 (SARS-CoV-2) can infect various human organs, including the respiratory, circulatory, nervous, and gastrointestinal ones. The virus is internalized into human cells by binding to the human angiotensin-converting enzyme 2 (ACE2) receptor through its spike protein (S-glycoprotein). As S-glycoprotein is required for the attachment and entry into the human target cells, it is the primary mediator of SARS-CoV-2 infectivity.
View Article and Find Full Text PDFPemphigus is a life-threatening auto-immune blistering disease of the skin and mucous membrane that is caused by the production of auto-antibodies (auto-Abs) directed against adhesion proteins: desmoglein 1 and 3. We demonstrated in the "Ritux3" trial, the high efficacy of rituximab, an anti-CD20 recombinant monoclonal antibody, as the first-line treatment for pemphigus. However, 25% of patients relapsed during the six-month period after rituximab treatment.
View Article and Find Full Text PDFImportance: The clinical relevance of antirituximab antibodies (ARAs) in patients with pemphigus who are treated with rituximab (RTX) is currently unknown.
Objective: To determine the prevalence of ARAs in patients with pemphigus who are treated with RTX and their association with complete remission (CR) and relapse.
Design, Setting, And Participants: This post hoc analysis of the Ritux3 trial was conducted from January 2010 to December 2015 in 25 dermatology departments in France and included 42 patients with moderate-to-severe pemphigus who were randomized to receive treatment with RTX.